What Happens to Your Heart When You Stop Taking GLP-1 Drugs?
The protection builds slowly and comes apart slowly. A study of over 333,000 U.S. veterans with type 2 diabetes found that the cardiovascular benefit of GLP-1 medications accumulated with continuous use, and that stopping or interrupting treatment eroded that benefit progressively, with risk climbing the longer someone stayed off the drug.
GLP-1 receptor agonists, the class of drugs that includes semaglutide (Ozempic, Wegovy) and liraglutide (Victoza), have become some of the most talked-about medications in medicine. Beyond helping control blood sugar and weight, these drugs have shown real heart-protective benefits. But this new study raises a critical question: what happens when patients stop taking them?
What the Data Show
The study drew on Veterans Affairs healthcare records from 1 January 2017 to 31 December 2023, comparing 132,551 people who started a GLP-1 receptor agonist against 201,136 who started a sulfonylurea, all with type 2 diabetes and all followed for three years. The outcome was the three year cumulative incidence of major adverse cardiovascular events, defined as myocardial infarction, stroke, or death from any cause. In the GLP-1 arm, treatment status was reassigned every six months, which let the researchers build 16 prespecified strategies covering different lengths of continued use, discontinuation, and interruption.
The relationship depended on duration. Compared with the sulfonylurea group, people who used a GLP-1 drug for 0.5, 1, or 1.5 years and then discontinued for the rest of the three years had incidence risk ratios close to 1.0, with no significant reduction in risk. Benefit became significant at longer exposures: 2 years of use before discontinuing gave an incidence risk ratio of 0.93 (95% CI 0.88 to 0.98), and 2.5 years gave 0.85 (0.81 to 0.90). People who stayed on the drug for the full three years had the largest reduction, an incidence risk ratio of 0.82 (95% CI 0.78 to 0.85).
The comparison against continued use tells the other half of the story. Measured against people who kept taking the drug, 0.5 years of discontinuation carried an incidence risk ratio of 1.04 (95% CI 1.01 to 1.08). Longer gaps did more damage: 1.14 (1.09 to 1.18) at one year off and 1.22 (1.16 to 1.27) at two years off. Interruptions followed the same gradient, with incidence risk ratios of 1.12 (95% CI 1.06 to 1.19) for one year of interrupted use and 1.16 (1.11 to 1.22) for two years. The authors concluded that the cardiovascular benefit accumulated with continuous use, and that even brief discontinuations or interruptions might progressively erode and could ultimately reverse that protection.
Dr. Kumar’s Take
This study changes how I frame the conversation about stopping. I see patients who want to come off their GLP-1 medication once they feel better or lose weight, assuming the heart benefit banks itself. The data point the other way: protection scaled with how long treatment continued, and time off the drug moved risk back in the wrong direction in a dose-dependent way. Two things follow for me clinically. First, a short course is unlikely to buy lasting cardiovascular benefit, since under half of the three year window on the drug showed no significant reduction against the comparison group. Second, gaps matter, and they matter more the longer they run, so a patient bridging a shortage or a coverage lapse is not in a neutral holding pattern. That does not mean nobody should ever stop. It means stopping deserves the same deliberation as starting, made with your physician, not defaulted into because you feel fine.
Who Was in This Study?
This was not a small clinical trial. The cohort included 132,551 incident users of GLP-1 receptor agonists and 201,136 incident users of sulfonylureas, all Veterans Affairs users with type 2 diabetes. Incident use meant no prescription for either drug class in the year before the first prescription, and Veterans Affairs users were defined as having at least two VA visits and having used the VA outpatient pharmacy within the year before treatment. The researchers used target trial emulation, which applies the design logic of a randomized trial to real-world medical records. That approach helps account for the many reasons patients start or stop a medication, giving more reliable results than a simple observational comparison.
Why People Stop and Why It Matters
Patients stop GLP-1 medications for many reasons. Side effects like nausea, cost and insurance issues, or simply feeling well enough to try going without are all common. Drug shortages have also forced some patients off their medications in recent years. Whatever the reason, this study suggests the decision to stop carries real cardiovascular consequences. The 22% higher risk after two years off the drug, relative to staying on it, is the number I keep coming back to, because the trend across 0.5, 1, and 2 years off ran in one direction the whole way. The benefit appears to depend on the drug continuing to work in the body.
Practical Takeaways
- Talk to your doctor before stopping any GLP-1 medication, even if you feel healthy, because the cardiovascular benefit in this study depended on staying on treatment.
- If cost or side effects are driving you to quit, ask about dose adjustments or switching to a different GLP-1 drug rather than stopping the entire class.
- Interruptions counted, not just permanent stops. If a shortage or a coverage gap is about to put you off the drug for months, treat that as a medical problem worth solving, not a pause.
- Patients taking GLP-1 drugs for heart protection should understand this is likely a long-term commitment, not a short-term fix.
- If you have already stopped, discuss your cardiovascular risk with your doctor and whether restarting makes sense for your situation.
Related Studies and Research
If you are interested in heart health and diabetes management, explore these related articles:
- Can L-Carnitine Help Your Heart? Exploring Its Benefits and Risks
- Red Yeast Rice May Lower Heart Risks in People with Metabolic Syndrome
- Creatine for Type 2 Diabetes: A Placebo-Controlled Trial
- PCSK9 Inhibitors and Cardiovascular Risk: Do They Really Reduce Heart Attacks and Strokes?
FAQs
What are GLP-1 drugs and why are they prescribed for heart health?
GLP-1 receptor agonists are a class of medications used to treat type 2 diabetes. In this study, people with type 2 diabetes who stayed on a GLP-1 drug for three years had an 18% lower risk of major adverse cardiovascular events, meaning heart attack, stroke, or death from any cause, than people who started a sulfonylurea. That kind of cardiovascular signal is why these drugs are now prescribed with the heart in mind and not only for blood sugar control.
Does this study mean I can never stop taking my GLP-1 medication?
Not necessarily, but it does mean stopping should be a deliberate medical decision. Risk rose in step with how long people stayed off the drug, from a 4% relative increase at six months off to 22% at two years off, compared with continued use. Every patient’s situation is different, and some people have other strong protective factors. The message is that you should not stop on your own without discussing it with your doctor, who can weigh your personal risk and help you make an informed choice.
Could restarting a GLP-1 drug after a break restore the heart benefits?
The study did examine interrupted use, meaning time off followed by a return to the drug, and interruptions were still associated with higher risk than continuous use: an incidence risk ratio of 1.12 (95% CI 1.06 to 1.19) for one year of interruption and 1.16 (1.11 to 1.22) for two years. So a break does not appear to be cost-free even when treatment resumes. If you have stopped and are considering restarting, your doctor can help evaluate whether that is the right move based on your current health.
Bottom Line
GLP-1 medications offered real, measurable heart protection in this study, with an 18% lower risk of major adverse cardiovascular events over three years of continuous use. That protection accumulated with time on the drug and eroded with time off it, in both directions by degree rather than all at once. If you are taking a GLP-1 medication for your heart, think of it as an ongoing partnership with the drug, not a one-time treatment. Talk to your doctor before making any changes.
